REMARKS

I. Amendments

A. In the Specification.

Paragraphs [0001], [0011], [0012], [0014]-[0017], [0032], [0039]-[0042], [0057], [0059] [0068]-[0070], [0077], [0079], [0080], and [0087] have been amended to clarify that the chelating compound is an amine and not an amide.

Paragraph [0082] has been amended to clarify that the recited halogenated transition metal compound in the paragraph, with its identified structure, is exemplary of the halogenated transition metal compound recited in step (ii) and not a halogenated transition metal compound in addition to that already recited in step (ii) of claim 1.

Similarly, paragraph [0083] has been amended to clarify that the recited organomagnesium compound in the paragraph, with its identified structure, is exemplary of the organomagnesium compound recited in step (ii) and not an organo-magnesium compound in addition to that already recited in step (ii) of claim 1.

Finally, paragraph [0084] has been amended to clarify that the recited compound having a Group 13 or Group 14 element, with its identified structure, is exemplary of the halogenized silicon compounds or halogenized boron compounds recited in step (ii) and not a halogenized silicon compound and/or halogenized boron compound in addition to that already recited in step (ii) of claim 1.

B. In the Claims.

Claims 1-12 are pending in the application. Claims 1, 3, 4, 6, 8, and 9 have been amended herein. Claims 1, 3, and 4 have been amended to clarify that the chelating compound is an amine and not an amide. Claim 1 has also been amended to clarify that in step (ii), the

magnesium halide composite support is treated with a halogenized transition metal compound and a chelating diamide compound in the presence of an organo-magnesium compound and also one or more compounds selected from the group consisting of halogenized silicon compounds and halogenized boron compounds. Support for this amendment can be found in the ABSTRACT and in paragraphs [0011], [0032], and [0033] of the Specification.

Claim 6 has been amended to clarify that the recited halogenated transition metal compound, with its identified structure, is exemplary of the halogenated transition metal compound recited in step (ii) of claim 1 and not a halogenated transition metal compound in addition to that already recited in step (ii) of claim 1. Support for this amendment can be found in paragraph [0082] of the Specification.

Claim 8 has been amended to clarify that the recited organo-magnesium compound, with its identified structure, is exemplary of the organo-magnesium compound recited in step (ii) of claim 1 and not an organo-magnesium compound in addition to that already recited in step (ii) of claim 1. Support for this amendment can be found in paragraph [0083] of the Specification.

Claim 9 has been amended to clarify that the recited compound having a Group 13 or Group 14 element, with its identified structure, is exemplary of the halogenized silicon compounds or halogenized boron compounds recited in step (ii) of claim 1 and not a halogenized silicon compound and/or halogenized boron compound in addition to that already recited in step (ii) of claim 1. Support for this amendment can be found in paragraph [0084] of the Specification.

II. Supplemental Election

In response to the April 28th phone conference with the Examiner, the following supplemental response to the Election Requirement is provided.

17

Regarding class (i), "various organo-silicon of claim 2", Applicants elect tetraethyl orthosilicate, a compound of the formula $Si(OR^1)_bR^2_{4-b}$ in which R^1 is ethyl and b is 4. Claim 2 reads on this elected species and claims 1 and 10 are generic.

Regarding class (ii), "various chelating diamides of claims 3-5 for treating the magnesium halide support", Applicants elect N,N'-di(2,6-diisopropylphenyl)-N,N'-di(trimethylsilyl)-1,2-ethane-diamine, a compound of claim 3 having the formula $R^1R^2N(CR^5_2)_xNR^3R^4$ in which R^1 and R^2 are each 2,6-diisopropylphenyl, R^3 and R^4 are each trimethylsilyl, R^5 is hydrogen, and x is 2. Claim 3 reads on this elected species and claims 1 and 10 are generic.

Three separate subclasses (a), (b), and (c) are identified for class (iii), "various method for treating the magnesium halide composite support." Regarding subclass (a), "halogenated transition metal compound of claims 6 and 7", Applicants elect $TiCl_4$, a compound of the formula $m(M^1X^1_a)\cdot n(M^2X^2_b)\cdot o(THF)$ of claim 6 in which m is 1, M^1 is Ti, X^1 is Cl, a is 4, n is 0, and o is 0. Claims 6 and 7 read on this elected species and claims 1 and 10 are generic.

Regarding subclass (b) of class (iii), "organo-magnesium compound of claim 8",

Applicants elect dibutyl magnesium, a compound of the formula R'MgR" in which both R' and
R" are butyl groups. Claim 8 reads on this elected species and claims 1 and 10 are generic.

Regarding subclass (c) of class (iii), "compound having the formula MR_{m-a}X_a of claim 9",

Applicants elect silicon tetrachloride, in which M is Si, X is Cl, m is 4, and a is 4. Claim 9 reads on this elected species and claims 1 and 10 are generic.

CONCLUSION

The Examiner is invited to contact the undersigned attorney with any questions, comments, or suggestions relating to the referenced patent application.

Respectfully submitted,

Customer Number 23369 Howrey Simon Arnold & White, LLP 2941 Fairview Park Drive, Box 7 Falls Church, Virginia 22042 (703) 336-6950 (Fax)

Date: May 3, 2005

Patricia A. Kammerer Reg. No. 29,775 713-787-1400

Attorney for Assignee Formosa Plastics Corporation, U.S.A.